- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06516341
Spatially and Temporally Resolving Predictive Biomarkers of Postoperative Recurrence and Complications in Chronic Intestinal Inflammation
A portion of patients with Inflammatory bowel disease often require surgical intervention since they do not respond to the current therapies. Besides this risk, patients may develop post-operative disease complications, and the factors beneath are far from being understood or predicted. The investigators hypothesize that some priming factors remain in the resection margin after surgery and act as a memory of the evolution of the disease, leading to the recurrence or complications. The following proposals are made:
- defining and validating in humanized experimental models of intestinal inflammation the spatial and temporal dynamics of the postoperative complications-priming factors
- integrating them into a machine-learning-driven model to determine risk indices of disease recurrence in IBD patients. This risk prediction model will not change the clinical decision-making process but will only be built for research. Consequently, patients enrolled in this study will be monitored and treated as per the standard of care.
This project will reveal possible causes and build methods predictive of postoperative complications ultimately resulting in changes in clinical management in the near future.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
A portion of patients with Inflammatory bowel disease often require surgical intervention since they do not respond to the current therapies. Besides this risk, patients may develop post-operative disease complications, and the factors beneath are far from being understood or predicted. The investigators hypothesize that some priming factors remain in the resection margin after surgery and act as a memory of the evolution of the disease, leading to the recurrence or complications. The following proposals are made:
- defining and validating in humanized experimental models of intestinal inflammation the spatial and temporal dynamics of the postoperative complications-priming factors
- integrating them into a machine-learning-driven model to determine risk indices of disease recurrence in IBD patients.
This risk prediction model will not change the clinical decision-making process but will only be built for research. Consequently, patients enrolled in this study will be monitored and treated as per standard of care. This project will reveal possible causes and build methods that could help predict postoperative complications ultimately resulting in changes in clinical management.
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Contact
- Name: Federica Ungaro, PhD.
- Phone Number: +39 0226437864
- Email: ungaro.federica@hsr.it
Study Contact Backup
- Name: Pierpaolo Sileri, MD. PhD.
- Phone Number: +39 0226436275
- Email: sileri.pierpaolo@hsr.it
Study Locations
-
-
-
Milan, Italy, 20132
- Recruiting
- IRCCS Ospedale San Raffaele
-
Contact:
- Federica Ungaro, PhD.
- Phone Number: +39 0226437864
- Email: ungaro.federica@hsr.it
-
Contact:
- Federica Ungaro, PhD
-
Contact:
- Luca Albarello, MD
-
Contact:
- Pierpaolo Sileri, MD, PhD.
- Phone Number: +39 0226436275
- Email: sileri.pierpaolo@hsr.it
-
Contact:
- Pierpaolo Sileri, MD, PhD.
-
Contact:
- Andrea Vignali, MD
-
Contact:
- Alice Frontali, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- adult (age >18 years) patients with histologically confirmed CD or UC undergoing intestinal resection due to stricturing disease, regardless of their current or past medical treatment;
- given that it is an observational study, also pregnant and breastfeeding patients could be included;
- able and willing to sign the informed consent.
Exclusion Criteria:
- patients <18 years or > 70 years;
- patients with unconfirmed both UC and CD diagnoses;
- patients with superimposed dysplasia or cancer diagnosis and resections for which post- operative endoscopic assessment of recurrence is not feasible;
- patients unable or unwilling to sign the informed consent.
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
|---|---|
|
UC patients
Patients with histologically confirmed UC undergoing intestinal resection due to stricturing disease. These patients will be divided into two groups: patients with (case group) and without (control group) postoperative recurrence |
The study will involve the collection of leftover surgical material after pathologist analysis, mucosal brushes, an additional volume of blood and feces of patients at the time of surgery
|
|
CD patients
Patients with histologically confirmed CD undergoing intestinal resection due to stricturing disease.
Divided into two groups: patients with (case group) and without (control group) postoperative recurrence
|
The study will involve the collection of leftover surgical material after pathologist analysis, mucosal brushes, an additional volume of blood and feces of patients at the time of surgery
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
To define spatial, cellular, and molecular characteristics of IBD-derived intestinal samples
Time Frame: 6 months from surgery
|
To define the spatial transcriptome of UC and CD-derived intestinal mucosa, IBD-derived tissues will be analized by spatial transcriptomics, either at molecular or at microbiota level on formalin-fixed paraffin-embedded (FFPE) tissues stored at our pathology unit.
|
6 months from surgery
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
To build the predictive model of postoperative complications based on spatially and temporally resolved IBD characteristics
Time Frame: 6-12 months from surgery
|
Other variables to be considered are CD4+ T-cells from the processing of blood
|
6-12 months from surgery
|
|
To determine the mechanism underlying post-operative complications by exploiting in-vivo (mouse) experimental models of intestinal inflammation.
Time Frame: 19-24 months from surgery
|
At the time of surgery, feces will be collected from patients.
The microbial component from the IBD surgical specimens will be isolated and injected into humanized animal models.
|
19-24 months from surgery
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- PNRR-MCNT2-2023-12377779
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Crohn Disease
-
Turku University HospitalUniversity of TurkuRecruitingInflammatory Bowel Diseases | Crohn Disease | Crohn Colitis | Crohn's Ileocolitis | Crohn Disease in Remission | Crohn Disease of Small IntestineFinland
-
Tzaneio General HospitalRecruitingCrohn Disease (CD) | Crohn Disease of Ileum | Kono S Anastomosis | Extended Mesenteric ExcisionGreece
-
L2 Bio, LLCFDAMap; Akan Biosciences, Inc.Not yet recruitingCrohn&Amp;#39;s | Crohn&Amp;#39;s Disease (CD)
-
University Hospital, Clermont-FerrandNot yet recruiting
-
Central Hospital, Nancy, FranceNot yet recruitingCrohn Disease (CD)France
-
GLSMED Learning Health S.A.Not yet recruiting
-
University Hospital, Clermont-FerrandActive, not recruiting
-
University Hospital, GrenobleNot yet recruiting
-
Groupe d'Etude Therapeutique des Affections Inflammatoires...RecruitingCrohn Disease (CD)France
-
Sixth Affiliated Hospital, Sun Yat-sen UniversityRecruiting
Clinical Trials on UC patients
-
Think Now IncorporatedUniversity of California, Berkeley; University of California, Los AngelesCompleted
-
KU LeuvenRecruiting
-
The Hospital for Sick ChildrenSickKids Foundation; The Cundill Centre for Child and Youth DepressionUnknownSuicidal Ideation | Suicide, Attempted | SuicideCanada
-
Stanford UniversityCompletedColorectal CancerUnited States
-
Göteborg UniversityWallström och Sjöbloms stiftelse; Peter Erikssons minnesfond; Back to LifeCompletedStroke | Brain DiseasesSweden
-
Universidad de ZaragozaCompleted
-
Chinese PLA General HospitalBeijing Friendship Hospital; Beijing 302 Hospital; The University of Hong Kong-Shenzhen... and other collaboratorsEnrolling by invitationSevere Aplastic Anemia | Severe Aplastic Anemia (SAA) | Severe Aplastic Anemia, RefractoryChina
-
Renmin Hospital of Wuhan UniversityWuhan Hamilton Biotechnology Co., LtdUnknownDiabetic NephropathyChina
-
Wuhan Union Hospital, ChinaWuhan Hamilton Bio-technology Co., Ltd, China.UnknownCOVID-19 | 2019 Novel Coronavirus PneumoniaChina
-
Puren Hospital Affiliated to Wuhan University of...Cancer Institute and Hospital, Chinese Academy of Medical Sciences; Shanghai... and other collaboratorsUnknown